Literature DB >> 2301438

Does prophylaxis prevent postdental infective endocarditis? A controlled evaluation of protective efficacy.

T F Imperiale1, R I Horwitz.   

Abstract

PURPOSE: Despite the American Heart Association's (AHA) recommendations for antibiotic prophylaxis to prevent infective endocarditis, no controlled clinical evidence exists for the effectiveness of this intervention. The purpose of this case-control study was to determine whether antibiotic prophylaxis for a dental procedure reduces the risk of infective endocarditis in persons with high-risk cardiac lesions. PATIENTS AND METHODS: Cases consisted of eight subjects with high-risk lesions (six mitral, one aortic, one uncorrected tetralogy) whose first-time, native-valve infective endocarditis occurred within 12 weeks of a dental procedure and was diagnosed between 1980 and 1986. For each case subject, three control subjects were chosen from patients who underwent echocardiographic evaluation between 1980 and 1986, and who were matched for the specific high-risk lesion and age. Use of antibiotic prophylaxis, which was determined by interviews with patients and supplemented by the dentists, was defined as antibiotic taken both before and after the dental procedure.
RESULTS: Antibiotic prophylaxis was used by only one of eight (13%) case subjects compared with 15 of 24 (63%) control subjects, for an odds ratio of 0.09, which is clinically impressive (indicating 91% protective efficacy) and statistically significant (p = 0.025).
CONCLUSION: Although this report does not specifically assess the value of antibiotic prophylaxis for the current AHA recommendations, the use of antibiotic prophylaxis in persons with high-risk cardiac lesions is supported by the magnitude of protective efficacy observed in this study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301438     DOI: 10.1016/0002-9343(90)90461-l

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.

Authors:  M S Rouse; J M Steckelberg; C M Brandt; R Patel; J M Miro; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Antibiotic prophylaxis for dental treatment.

Authors:  R A Cawson
Journal:  BMJ       Date:  1992-04-11

Review 3.  Controversies in perioperative medicine.

Authors:  H Q Cheng
Journal:  West J Med       Date:  1998-12

4.  Antibiotic prophylaxis of endocarditis: the rest of the world and NICE.

Authors:  John B Chambers; David Shanson; Roger Hall; John Pepper; Graham Venn; Mark McGurk
Journal:  J R Soc Med       Date:  2011-04       Impact factor: 5.344

5.  Infective endocarditis: some popular tenets debunked?

Authors:  S J Eykyn
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

6.  Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis.

Authors:  P Krijnen; C J Kaandorp; E W Steyerberg; D van Schaardenburg; H J Moens; J D Habbema
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 7.  Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.

Authors:  B Capitano; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 8.  Recognition, management and prophylaxis of endocarditis.

Authors:  D Stamboulian; E Carbone
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

9.  Bacteremia associated with toothbrushing and dental extraction.

Authors:  Peter B Lockhart; Michael T Brennan; Howell C Sasser; Philip C Fox; Bruce J Paster; Farah K Bahrani-Mougeot
Journal:  Circulation       Date:  2008-06-09       Impact factor: 29.690

Review 10.  Pathogenesis and prevention of native valve infective endocarditis in elderly dental patients.

Authors:  A H Friedlander; C E Marshall
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.